Skip to content
Mavacamten
Camzyos (mavacamten) is a small molecule pharmaceutical. Mavacamten was first approved as Camzyos on 2022-04-28.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Camzyos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mavacamten
Tradename
Company
Number
Date
Products
CAMZYOSBristol Myers SquibbN-214998 RX2022-04-28
4 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
camzyosNew Drug Application2022-04-28
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
MAVACAMTEN, CAMZYOS, BRISTOL
2029-04-28ODE-398
2027-04-28NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Mavacamten, Camzyos, Bristol
91812002034-06-19DS, DP
95858832034-06-19U-3373
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hypertrophic cardiomyopathyD002312EFO_0000538I42.1246——11
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50—1———1
Ventricular outflow obstructionD014694EFO_1001448—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—6————6
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMAVACAMTEN
INNmavacamten
Description
Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy.
Classification
Small molecule
Drug classallosteric cardiac myosin modulators
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
Identifiers
PDB—
CAS-ID1642288-47-8
RxCUI—
ChEMBL IDCHEMBL4297517
ChEBI ID—
PubChem CID117761397
DrugBankDB14921
UNII IDQX45B99R3J (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Camzyos - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 396 documents
View more details
Safety
Black-box Warning
Black-box warning for: Camzyos
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details